Juergen May studied biology and completed his PhD in genetics at the Philipps-University in Marburg. He spent the first years of his career in a biotech start-up company in Germany working on a peptide platform to identify and research new antibiotics. In 2005 he joined Roche where he has held a number of roles across the pharma value chain, including pharma technical development, risk management and CMC project management. Juergen was involved in the launch of Actemra and acted as scientific expert for multiple in-licensing projects of the Roche Pharma Partnering organization. In 2016 he joined the Roche Innovation Partnering team as Global Business Development manager. In this position he is responsible for scouting and assessing new business development opportunities across different therapeutic areas with a focus on early stage discovery and platform technologies.
MEET JUERGEN MAY AT #KFG2018
Juergen May will give a presentation in the session "Partnering Opportunities", together with Cedric Ververken.
"How Confo Therapeutics and Roche joined forces to crack an ‘undruggable’ GPCR"
Both companies will introduce their partnering objectives and describe where the Confo/Roche collaboration and license agreement fits in. Next we will review the different steps in the discussion (eg. how was the first link established, what the key steps were after that etc.), and briefly outlined how the deal was structured, and how this deal fits in both companies’ partnering objectives.